Domani Wealth LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,569 shares of the company’s stock after selling 115 shares during the quarter. Johnson & Johnson comprises about 0.9% of Domani Wealth LLC’s portfolio, making the stock its 22nd biggest position. Domani Wealth LLC’s holdings in Johnson & Johnson were worth $2,402,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $25,000. Krane Funds Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $26,000. Crewe Advisors LLC boosted its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares in the last quarter. Permanens Capital L.P. boosted its position in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after acquiring an additional 100 shares in the last quarter. Finally, Thor Advisors LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $69,000. Institutional investors own 72.01% of the company’s stock.
Johnson & Johnson stock opened at $131.33 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The stock has a market capitalization of $341.03 billion, a price-to-earnings ratio of 14.85, a PEG ratio of 2.18 and a beta of 0.69. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The business has a fifty day moving average price of $129.92 and a 200-day moving average price of $134.97.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.10 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 8.59 earnings per share for the current fiscal year.
JNJ has been the topic of several recent research reports. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research report on Thursday, July 18th. Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Raymond James dropped their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Finally, Barclays initiated coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $151.00.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Catch-Up Contributions
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.